AJU Medical

Aju Pharmaceutical, the first in Korea and the second in the world to successfully mass-produce tuberculosis treatment, has grown into a total healthcare group that enhances the well-being of individuals from diagnosis to treatment and prevention. We supply over 290 essential prescription drugs for critical diseases in the medical field. Additionally, starting with anchors, which were previously absent in the domestic market, we have expanded our sports medicine products globally. Furthermore, by utilizing eco-friendly ingredients such as olive leaf extract, we provide a wide range of health functional foods for preventive care.

1953

Established Aju Pharmaceutical Industry Co., Ltd.
Kwangnam Kim appointed as CEO
Launched Asiazit, Korea’s first and the world’s second tuberculosis treatment

1959

Introduced Compural, an antipyretic and analgesic, through a technology partnership with Bayer (West Germany)

1961

Launched Avomin, an anti-nausea and motion sickness treatment, through a partnership with May & Baker (UK)
Introduced Almiaspas, a tuberculosis treatment, in collaboration with Tanabe Pharma (Japan)

1963

Expanded injection production facilities

1964

Released Iphigit, a tuberculosis treatment, in collaboration with Tanabe Pharma (Japan)
Awarded the Presidential Citation for contributions to the tuberculosis eradication program

1966

Developed Korea’s first short-acting general anesthetic, Labonal-M Injection, in collaboration with Tanabe Pharma (Japan)

1967

Constructed a new raw material synthesis plant

1975

Awarded the Minister of Health and Welfare Citation for contributions to synthetic raw material exports

1977

Awarded the Minister of Health and Welfare Citation for contributions to the advancement of export products

1978

Awarded the Minister of Health and Welfare Citation for outstanding contributions to wartime mobilization preparedness

1979

Awarded the Minister of Commerce and Industry Citation for contributions to national industrial development

1983

Joo Jae-soon appointed as the 2nd Chairman
Kim Joong-gil appointed as the 2nd CEO

1984

Selected as a Promising Small and Medium Enterprise by the Ministry of Science and Technology

1986

Discontinued raw material synthesis business and transitioned to finished pharmaceutical manufacturing and sales

1990

Introduced the Vessel Due capsule, a treatment for hyperlipidemia, through a technical partnership with Alfa Wassermann (Italy)

1992

Constructed a new headquarters building in Guro
Built a new KGMP-certified plant in Pyeongtaek

1995

Established the Central Research Institute

1996

Began producing and supplying Profenid Injection for Rhone-Poulenc Rorer Pharmaceuticals

1998

Produced and supplied Norcuron Injection and Decaduralin Injection for Organon Korea

1999

Introduced the probiotic Jeongjangsaeng Capsule through a partnership with China’s Jeil Jeyakchang
Launched the Vessel Due F capsule, an antithrombotic treatment, in collaboration with Alfa Wassermann (Italy)

2002

Released the urinary tract infection treatment Urovaxom through a technical partnership with OM Pharma (now Vifor Pharma, Switzerland)

2004

Produced and supplied PaoSchool Injection for Torii (Japan)

2006

Launched the Bronchovaxom COPD treatment through a technical partnership with OM Pharma (now Vifor Pharma, Switzerland)

2007

Established the Olea division, a brand specializing in olive leaf health products

2009

Completed a dedicated manufacturing plant for cephalosporin antibiotics

2010

Established the Medical Business Division (entry into the medical device sector)

2011

Launched the Medical Device Business
Changed company name from Aju Pharmaceutical Industry Co., Ltd. to Aju Pharmaceutical Co., Ltd.

2012

Approved as a foreign manufacturer by Japan’s PMDA (Ministry of Health, Labour and Welfare)
Signed a technology transfer contract for asthma treatments at the Biomedical Research Institute
Recognized for achieving $1 million in exports and awarded the Presidential Citation

2013

Signed a technology transfer agreement and industry-academia partnership with Dongguk University Medical Device Development Center
Established the Regencare Joint Venture with burn treatment hospital Bestian

2014

Completed the construction of the Bundang plant for the medical business division

2015

Launched Korea’s first immediate-release PPI, Zeroseed Tablet
Released the stool regulation agent Rexil Tablet
Introduced the acute and chronic gastritis treatment Asica Tablet
Released the hypertension combination drug Rozadipine Tablet

2016

Completed a dedicated solid dosage manufacturing facility
Certified as a youth-friendly small and medium enterprise

2017

Joo Jae-soon appointed as the first honorary chairman
Kim Joong-gil became the 3rd chairman
Korea’s first Fixone Anchor FDA approval
Achieved KRW 100 billion in sales at Aju Pharmaceutical Co., Ltd.
Launched the children’s healthcare brand olki
Released the best-selling Allkey Vita Jelly 3 varieties

2018

Obtained the first export approval for the Cretrol Tablet (improved drug) in Latin America
Received the Sincere Model Taxpayer Award from Guro District Office

2019

Hosted the Vision 2030 Workshop
Received the Sincere Taxpaying Workplace Award from Gyeonggi Province

2020

Kim Tae-hoon inaugurated as the 3rd CEO
Conducted remote video interviews for new hires due to COVID-19
Conducted anti-bribery internal auditor training
Obtained ISO 37001 Anti-Bribery Management System certification
Distributed COVID-19 support funds to all employees
Awarded Prime Minister’s Citation on Labor Day for significant contributions

2021

Achieved KRW 10 billion in sales for Urovaxom Capsule
Received Minister of Employment and Labor Citation for labor-management cultural contributions
Received Governor of Gyeonggi Province Award on Commerce Day
Launched Saponadil SR Tablet
Implemented next-generation ERP (SAP) system
Created a smart office environment at headquarters
Secured GMP approval in Eurasian Economic Union (EAEU) for Urisia
Established Aju Pharmaceutical Co., Ltd. Distribution Business Division
Aired first TV commercial for Allkey Vita Jelly

2022

Achieved KRW 10 billion in sales for Cretrol Tablet
Released Tennes Tablet, a DPP4-inhibitor for diabetes treatment
Aired TV commercial for Allkey Nutritional Jelly
Expanded Allkey health functional foods and health juice offerings

2023

Remodeled and relocated the Quality Control Center
Released Daparyl Tablet, a diabetes treatment
Launched Pimaten Tablet, a hypertension treatment
Produced Daparyl Tablet (SGLT-2 inhibitor) in-house
Initiated new Allkey X Seojun Mom campaign
Collaborated with Hello Carbot to create Allkey Calcium Jelly

2024

Implemented smart office work environment (hub offices + shared offices)
Hosted a roundtable meeting on the labor and childcare support system, chaired by the Minister of Employment and Labor
Awarded Prime Minister’s Citation on Labor Day for exceptional contributions
Held Town Hall Meeting at Lotte Sky 31
Began nationwide sales representative activities for all hospital/clinic accounts under Aju Pharmaceutical Co., Ltd.
Released the world’s first combination diabetes drug, Dafarina Tablet (Dapagliflozin + Linagliptin, improved drug produced in-house)
Reached KRW 193.8 billion in prescription performance for 2024
Achieved KRW 28.8 billion in prescriptions for Cretrol Tablet (produced in-house)
Reached KRW 24.5 billion in prescriptions for the recurrent and chronic urinary tract infection treatment Urovaxom Capsule (produced in-house)
Aired the industry’s first AI advertisement for children’s health foods

2025

Established Aju Holdings Co., Ltd.
Established Aju Alliance Co., Ltd.
Established Aju Medical Co., Ltd.
Established Aju Healthcare Co., Ltd.